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In the past decade approximately forty-eight bil-
lion milliequivalents of a single oral potassium chlo-
ride preparation have been produced and sold by a
single pharmaceutical man ufacturer (WETTER M S,
Ciba Pharmaceutical Co., June, 1976, personal com-
munication). Precise figures for the total quantity of
potassium prescribed annually are not available, but
an estimate of 20 to 30 billion milliequivalents is
probably reasonably accurate. It is also a reasonable
assumption that a substantial fraction of this elec-
trolyte supplement is prescribed to prevent or to treat
the hypokalemia and potassium deficiency generally
thought to result from diuretic therapy. The con-
clusion seems inescapable, considering the enormous
amounts of potassium prescribed, that the majority
of physicians feel confident that routine treatment
with an oral potassium preparation is warranted in
patients receiving diuretic therapy. This opinion is
maintained even though several recent studies have
raised serious question about the need for such ther-
apy and have also pointed out the potential risk of
treatment [1—61. Indeed, the casual approach to the
administration of potassium contrasts sharply with
the cautious approach to the use of a drug such as
chloramphenicol, even though the ratio of risk to
benefit is probably considerably higher for potassium
salts as compared to the antibiotic.
The purpose of this review is to discuss the magni-
tude of potassium deficiency in patients receiving diu-
retics, the influence of diuretic-induced acid-base de-
rangements on potassium balance, the necessity and
effectiveness of therapy with potassium salts and po-
tassium conserving drugs and, finally, the benefits
and costs of therapy.
Mechanismsof potassium loss with diuretics
A detailed discussion of renal potassium-handling
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and the factors which control it is found elsewhere in
this symposium [7]. Current concepts hold that fil-
tered potassium is totally reabsorbed in the proximal
tubule and that the potassium which appears in the
urine is a product of distal tubular potassium secre-
tion. Distal potassium secretion is a function of the
passive forces generated by the transepithelial poten-
tial difference and the concentration gradient for po-
tassium between tubular cells and the tubular fluid
across the luminal cell membrane. The existence in
the distal tubule of a tightly linked sodium-cation
(potassium and hydrogen) "exchange" system has
not been supported by recent experiments [8, 9].
However, the increase in sodium delivery to the distal
tubule that occurs following acute administration of
diuretics, including the thiazides, chiorthalidone, fu-
rosemide, and ethacrynic acid, does lead to an in-
crease in potassium excretion [8, 10]. Whether the
potassium deficit thus created persists, increases, or
decreases following a diuretic-induced potassium
loss is a function principally of the capacity of the
kidney to conserve ingested potassium. During pe-
riods of continuous diuretic therapy, potassium
losses in the urine often equal or exceed intake
levels. When such is the case', the deficit will persist or
increase. Of course, if the intake of potassium is very
high, a positive balance for potassium will be
achieved, even if continuous administration of diuret-
ics yields a substantial daily urinary potassium loss.
Even if diuretics are no longer being administered,
however, other mechanisms may impede correction
of a diuretic-induced potassium deficit. Factors such
as hyperaldosteronism, dietary salt restriction, and
alterations in acid-base equilibrium may so accelerate
the renal excretion of potassium that neither the po-
tassium content of the diet nor supplemental potas-
sium therapy is sufficient to overcome the renal
losses.
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The problem posed by diuretic-induced metabolic
alkalosis is particularly pertinent. The loss of potas-
sium consequent on diuretic administration is a meta-
bolic side effect of a treatment designed primarily to
deplete the body of salt and water. The loss of so-
dium, chloride, and water has a profound effect on
the kidney and leads to an acceleration of hydrogen
secretion (and thus to metabolic alkalosis) and to an
acceleration of tubular potassium secretion. Both in
patients with metabolic alkalosis induced by diuretics
and in normal individuals made alkalotic by sodium
nitrate infusions, a daily intake of over 100 mEq of
potassium fails to fully correct the potassium deficit,
even in the face of potassium deficits as large as 450
mEq, unless the existing chloride deficit is also re-
paired [11]. In any patient previously treated with
diuretics, the persistence of a potassium deficit is
almost certainly not the result of inadequate dietary
intake of this ion, since virtually all diets contain
ample amounts of potassium (60 to 70 mEq per day).
As noted earlier, maintenance of a high rate of renal
potassium excretion is the most common cause of a
lasting deficit in this situation.
Differences in the deficit of potassium between
nonedematous and edematous patients given diuret-
ics can be readily anticipated based on factors such as
the state of acid-base equilibrium and the sodium
chloride intake. Thus, patients treated with diuretics
for edema are usually on a salt-restricted diet and
often develop metabolic alkalosis complicated by a
persistent substantial potassium deficit. On the other
hand, patients given diuretics for hypertension are
usually not severely salt-restricted and, thus, typically
do not develop metabolic alkalosis; under these cir-
cumstances, a significant potassium deficit would not
be anticipated. The need for potassium and chloride
replacement therapy in these two types of patients
differs greatly.
Observations on potassium deficiency during diuretic therapy
Given the expected differences in the potassium
deficits induced by diuretics in edematous patients
subjected to rigorous salt restriction and nonedema-
tous patients subjected to little or no salt restric-
tion, the data regarding diuretic administration to
nonedematous (hypertensive) patients will be ana-
lyzed separately from the data obtained in edematous
patients. Before presenting these findings, however,
the serious limitations of interpreting the available
data must be considered,
Problems ojassessing the data. In order to quantify
the potassium deficit induced by diuretic therapy,
certain criteria must be met. First, there must be
accurate methods for measuring body potassium
stores. Second, suitable control data must be avail-
able for comparison. Ideally, the status of the potas-
sium stores of the patient before receiving therapy
must be known, or, alternatively, data from patients
during therapy must be compared to that of matched
untreated individuals. Third, potassium deficits re-
sulting from causes other than diuretic therapy must
be factored out. Unfortunately, many of the pub-
lished studies on potassium deficiency in patients re-
ceiving diuretics have not taken cognizance of one or
more of these points.
Numerous studies have shown that the correlation
between serum potassium concentration and total
body potassium stores is not a close one, even in the
absence of complicating acid-base disturbances
[12—14]. For this reason investigators have been re-
luctant to rely on serum potassium measurements as
an indicator of the extent of a potassium deficit.
Balance studies are reliable over short periods, but
long-term balance measurements are difficult to carry
out, and the reliability of such studies is questionable
because of large systematic errors that accumulate.
For these reasons, most investigators have turned to
measurements of total body potassium using isotopic
methods. Unfortunately, these methods also have
considerable drawbacks.
By direct chemical analysis, total body potassium
in the normal adult is approximately 55 mEq/kg of
body wt (3500 to 4000 mEq), of which 95 to 98% is
located intracellularly [IS, 16]. The whole body
counting method using radioactive potassium (40K)
(TB40K) gives values for total body potassium that
are approximately 50 to 55 mEq/kg of body wt in the
male and 40 to 50 mEq/kg in the female; but wide
variations exist even among normal individuals as a
result of differences in muscle mass and fat content
[17, 18]. In a recent study of more than 3,000 normal
volunteers in which factors such as age, sex, height
and relative fat content were considered, reliable in-
formation has been obtained on total body potassium
content [19]. If "fat-free" weight is defined as body
wt minus body fat (estimated by anthropometric mea-
surements), it is possible to define an age-specific
normal range for total body potassium. Even with
such cautious methodology, however, the variance
still averages 10% within any five-year age bracket.
Even more pertinent to the issues considered in this
paper is the conclusion that a 20% reduction in total
body potassium must exist in order for such a deficit
to be detected with 95% probability if only a single
measurement is made. A change in total body potas-
sium of as little as 5% (l75 to 200 mEq), however,
can be detected with the same statistical confidence if
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serial measurements are carried out in a single sub-
ject.
Measurements of total body potassium also can be
made using isotope dilution techniques. Studies using
42K (Ke) give values approximately 15% lower than
the whole body counting method [20] with mean
values in males of approximately 46 mEq/kg of body
wt [21] and in females approximately 29 to 32
mEq/kg [12, 22]. Estimated standard errors of this
technique range from 3 to 10%, and it seems likely
that just as with the TB40K method, when serial mea-
surements are made in the same individual a change
in body potassium content of at least 5% (l75 to
200 mEq) is required before a satistically significant
difference can be detected [12, 21—25]. The equipment
required for both of these techniques is relatively
complex, and for this reason, the techniques generally
are not available to most physicians.
The difficulties imposed by TB40K or Ke method-
ology as well as the difficulty in estimating total body
water or fat content have led investigators to turn to
potassium-loading tests or to analyses of the potas-
sium content of red blood cells [26], muscle cells [14,
27, 28], or white blood cells [29—31] as indirect in-
dicators of body potassium stores. Measurement of a
24-hr urine potassium excretion following adminis-
tration of a standard potassium load has been em-
ployed as a means of qualitatively evaluating potas-
sium deficiency in various clinical conditions,
including patients treated with diuretics [32]. The
oral potassium test is performed easily, but it is a
qualitative test only and has not been correlated with
TB40K, Ke, or balance measurements. Assessment of
cellular potassium content is also unsatisfactory from
a clinical standpoint as an index of total body deple-
tion. Red cell potassium content appears to be related
more closely to hemoglobin content and is poorly
correlated with Ke [26]. Muscle potassium content is
well correlated with TB40K measurements [14], but
such studies require that tissue be obtained by biopsy.
Potassium analysis of white blood cells shows some
promise as an investigative or clinical tool in deter-
mining changes in potassium stores in many different
situations, including patients receiving diuretics [33].
More studies of this method are required, however,
before it can be adopted for routine clinical use [34].
Potassium balance in diuretic-treated hypertensive
patients: The available data on the effect of long-term
diuretic therapy on serum potassium concentration
and total body potassium are summarized in Table I
in a fashion modified from that described elsewhere
[35]. The data clearly show that treatment for periods
as short as one month or as long as several years is
associated with a mild to moderate reduction in Se-
rum potassium concentration ranging from 0.3 to 1 .2
mEq/liter. Typical serum concentrations average 3.3
to 3.8 mEq/liter, and values below 3 mEq/liter are
encountered only infrequently.
Documentation of depletion of body potassium
stores in these patients is considerably less definite
than the observations of serum potassium concentra-
tion. Differences in the dosage of drugs, duration of
therapy, intake of sodium chloride and potassium,
and methodologic problems make interpretation of
these data difficult. As can be seen in Table I, how-
ever, the cumulative potassium deficit was less than
200 mEq in the majority of the patients receiving
thiazide diuretics who were tested during the 1960's
[36—41] , except in two reports, one of which is not
representative because the patients were ingesting a
low potassium diet [40]. In studies reported sub-
sequently, there appears to be agreement that little or
no potassium deficiency occurs in hypertensive pa-
tients receiving thiazide diuretics or furosemide: in
several studies there was either no significant differ-
ence from control, or the cumulative potassium defi-
cit was less than 200 mEq [1, 6, 35, 42—45]. Data on
chiorthalidone are less plentiful. While cumulative
potassium deficits of up to 300 mEq were reported
after prolonged drug administration in one study [I],
no significant potassium depletion was found in two
other studies [35,46].
In addition to these direct measures of body potas-
sium stores, other techniques also suggest that at
most a small deficit exists in hypertensive patients or
in normal volunteers treated with oral diuretics.
Studies of white cell and muscle potassium during
treatment with various agents indicate that the deficit
in such individuals is no larger than 4 to 6% of total
body stores [33, 47, 48].
Potassium balance in diuretic-treated edematous pa-
tients: TB40K and Ke measurements in edematous
patients with cardiac or hepatic disease consistently
demonstrate a substantial fall in potassium stores
in comparison to matched normal controls. This
depletion is usually unassociated with a fall in se-
rum potassium concentration, is often unaffected
by attempts to repair the deficit by potassium ad-
ministration, and is known to occur in the absence
of diuretic therapy [49—58]. This depletion in body
potassium stores is in part a reflection of the reduc-
tion in lean body mass that accompanies the poor
nutritional state of patients with heart and liver dis-
ease, but it also may be due to an additional signifi-
cant loss of intracellular potassium [55, 57, 58]. A
number of clinically important conclusions have been
drawn from these observations. First, the absolute
value of exchangeable potassium has been of con sid-
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erable prognostic value in some studies [52, 53]. Sec-
ond, a comparable degree of potassium depletion has
been noted in patients with congestive heart failure
whether or not they receive diuretics [56]. Third,
using the experimental technique of leukocyte elec-
trolyte measurements discussed above, an absolute
intracellular potassium deficiency has been found
which was not corrected by potassium supplements
of 30 to 50 mEq/day [33]. Indeed, when potassium
supplements are discontinued in diuretic-treated pa-
tients with cardiac edema, no significant change in
plasma, red blood cell, and total body potassium
concentrations is observed [59]. Finally, with success-
ful reversal of congestive heart failure or restoration
of normal hepatic function, exchangeable potassium
stores often return to values near those of com-
parable control groups. This restoration may occur
despite continued use of diuretics [53, 56, 601, These
isotope studies corroborate earlier metabolic balance
studies which also showed potassium retention dur-
ing diuretic treatment of cardiac failure [61, 62].
In view of this baseline level of potassium deple-
tion, identification of superimposed diuretic-induced
potassium deficiency is particularly difficult. The
problem is further compounded by a lack of specific
details on other factors that could influence potas-
sium balance. In many instances in which total body
potassium was measured, for example, detailed clini-
cal histories of the patients studied are not provided.
In addition, although investigators usually report
whether or not their subjects had gross cardiac or
hepatic failure or edema, other critical features such
as the dietary sodium chloride intake, the duration of
diuretic ingestion, the acid-base equilibrium, the ex-
tent of potassium supplementation, and the nutri-
tional status of the patient are often inadequately
Table I. Summary of studies of total body potassium content using isotopes of potassium in hypertensive patients receiving diuretics
Serum potassium
Reference
no.
Drug and dose
mg/day
No. of
patients
Duration of
therapy
weeks
mEq/liter Mean potass urn deficit
before after mEq pa Method
36 Chlorothiazide
375 to 750 12 4 to 8 4.4 3.6 85 0.02
37 Hydrochlorothiazide
tOO 20 4 4.4 3.8 0 NS 2K
37
38
Bendroflumethiazide
10
Chlorothiazide
17
20
4
6 to 8
4.5 3.9
4.2 3.4
0
165
NS
0.05
42K
12K
38 l-lydrochlorothia7ide 5 4 — — 405 0.001 2K
39
39
Thiazides
SOOto 1500
500 to 1500
5
5
2
8 to 32
4.0 3.7
4.0 3.8
130
0
NS
NS K
40 1-lydrochlorothiazide
100 33 7 4.2 3.3 412 0.01 42K
41 Hydrochlorothiazide
100 17 12 4.4 3.5 6 NS 2K
I Chtorthalidone
l00(everyotherday) 13 3to6 —0.5 236 NS 42K
1 Chiorthalidone
I00(every other day) 13 8to 15 —0.7 317 0.01 4K
I Furoscmide
80 9 lOto 15 —0.6 247 NS 5K
42
42
Ilydrochlorothiazide
00
Furosemide
0
9
8
8
4.2 3.4
4.2 3.9
l7
1—2
N5
NS
40K
40K
43 Hydrochlorothiazide
50 12 40 4.4 4.0 97 NS "0K
44 Bendroflumethiazide
10 5 1 to3yr — 3.9 100 NS 40K
44 Bendroflumethiazide
10 5 I to3yr — 3.5 180 — 40K
35 Chlorthalidone
100 (every other day) 26 14 — — 106 — 40K
45
6
Furosemide
40
Bendroflumethiazide
8
18
52
52
3.9 3.6
4.3 3.9
95l20 NSNS ""K""K
"P value for the difference from control of the potassium deficit. NS not significantly different from control.
"These patients were ingesting a low potassium diet.
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described. An equally important factor that clouds
interpretation is the lack of paired observations in the
same patient before and after treatment.
Because of those difficulties, any conclusion as to
the frequency and extent of an additional moiety of
potassium deficiency in edematous patients receiving
diuretics must be considered speculative. It is pos-
sible, however, to make certain assumptions about
this type of patient and their responses to treatment.
First, they are almost invariably sodium-avid as a
result of cardiac, hepatic, or renal disease, and their
diets are low in sodium chloride in an effort to deter
further fluid accumulation. Second, diuretics which
act in the ascending limb of Henle's loop (furose-
mide, ethacrynic acid) or the early distal tubule
(thiazides) increase excretion of sodium and chloride
in roughly equal proportions. It is well documented
that this is precisely the milieu in which metabolic
alkalosis develops, accompanied by a moderately se-
vere potassium deficiency. As noted earlier, once al-
kalosis and potassium deficiency develop, they are
sustained until a chloride supplement is made avail-
able. It seems likely, therefore, that edematous pa-
tients treated with diuretics often have a moderate to
severe reduction in body potassium stores that is
partially correctable by administration of potassium
chloride. It should be pointed out that the potassium
deficiency in such patients is resist'nt to correction by
supplements, such as potassium citrate or potassium
gluconate, unless chloride is made available at the
same time. Potassium chloride, of course, fully cor-
rects the diuretic-induced potassium deficiency and
the metabolic alkalosis [Ill.
It must be recognized that potassium loss could
occur in diuretic-treated patients as a result of mecha-
nisms other than those that influence acid-base equi-
librium. Diuretics themselves promote potassium
loss, and hyperaldosteronism may either enhance de-
pletion or impede the correction of a deficit. To the
extent that these factors operate, potassium deficits
would be expected even in the absence of metabolic
alkalosis.
Risks of potassium deficiency
Severe potassium depletion is known to interfere
with renal tubular function, increase the propensity
of the heart to digitalis-induced arrhythmias, impair
glucose tolerance, and in its most severe forms, im-
pede the contraction of skeletal muscle. Most studies
of the effects of potassium deficiency have been car-
ried out either in experimental animals or in patients
with severe depletion, rather than the negligible to
mild depletion observed in hypertensive patients re-
ceiving diuretics. In this light it is of interest that a
survey of a large number of hospitalized patients
receiving potassi urn-depleting diuretics without po-
tassium supplements showed that hypokalemia was
uncommon and, when present, was not life-threat-
ening. Only 4.9% of 1,294 patients surveyed de-
veloped hypokalemia, and none of the hypokalemic
patients suffered a serious complication attributable
to the potassium deficit [63].
The renal tubular functions known to be affected
by potassium deficiency in normal man or experimen-
tal animals include concentrating capacity and
urinary acidification [64, 65]. Studies in patients re-
ceiving diuetics, however, have shown little or no
alteration in renal function. The most extensive study
involved 17 hypertensive patients who had received
chlorthalidone for two to four months. In seven of
these individuals, despite a mean potassium deficit of
380 mEq, no changes from control values were de-
tected in minimum urinary pH or maximum urinary
osmolality [1]. In addition, rio symptoms referable to
potassium depletion, such as fatigue and polyuria,
were noted. There has been no report of potassium
depletion nephropathy secondary to diuretic therapy,
presumably because the tubular changes occur only
when the potassium deficit is severe. There is consid-
erable evidence, on the other hand, that the diluting
capacity of the kidney is impaired in patients receiv-
ing certain diuretics, and this disturbance has occa-
sionally led to water retention and the syndrome of
inappropriate secretion of antidiuretic hormone [66].
This disturbance in dilution has been attributed to
potassium depletion consequent on diuretic therapy,
but other mechanisms have not been excluded. In
fact, there are convincing reasons to believe that po-
tassium deficiency may be a result, rather than a
cause, of the overhydrated hyponatremic state [67].
There are conflicting views on the effect of diuretics
on carbohydrate metabolism. Several studies show
no alteration in blood glucose or glucose tolerance
even in the face of potassium deficits of 6% [1,42, 68].
In other studies, mild defects in glucose tolerance
have been identified in potassium deficient individuals.
Diabetes, however, did not develop in patients who
were not previously diabetic, and even the patients
with diabetes did not become markedly hyper-
glycemic [69, 70]. Moreover, in one study, the increase
in blood sugar showed no relation to the alteration in
serum potassium [70]. The observation that three-
quarters of a group of patients with hyperglycemic
coma had been treated with thiazides or furosemide
raised the possibility that the potassium deficiency
contributed to the metabolic state, but further obser-
vations on such patients are required to confirm this
hypothesis [71]. In fact, given the propensity of
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diazoxide, a congener of the thiazides with no diu-
retic properties, to suppress insulin release and ele-
vate blood sugar [72], it is possible that the modest
hyperglycemia associated with thiazide diuretics is
independent of its influence on electrolyte metabol-
ism.
In contrast to the lack of serious problems in
hypertensive patients receiving diuretics, the risk to
edematous patients with cardiac disease from hypo-
kalemia and potassium deficiency may be substantial.
Potassium depletion increases the danger of ar-
rhythmias in patients receiving digitalis, although the
degree of depletion does not correlate well with the
frequency of intoxication [73]. Patients receiving digi-
talis and diuretics are often also subjected to re-
stricted intakes of sodium chloride and, as described
earlier, are more likely to develop potassium defi-
ciency. Deterioration in consciousness in patients
with advanced liver disease and impending hepatic
coma has been attributed to electrolyte abnor-
malities, especially potassium deficiency. Given the
multiplicity of factors that precipitate hepatic coma
in such patients, however, it is not surprising that the
independent role of potassium deficiency has been
difficult to ascertain. One recent detailed in-
vestigation indicates that "profound" electrolyte dis-
turbances are correlated with the development of he-
patic pre-coma, but that hypokalemia perse did not
appear to be directly responsible for the deterioration
in the state of awareness [74].
Effectiveness of potassium therapy
In nonedematous patients receiving thiazide diu-
retics, supplemental potassium chloride therapy (60
mEq/day) raises serum potassium concentration to
normal in most patients. A minority of patients, how-
ever, remain hypokalemic despite the daily adminis-
tration of this supplement in doses as large as 100
mEq [75]. Restoration of body potassium content
can also be achieved in patients receiving chlorthali-
done, either by the simultaneous administration of
spironolactone or potassium chloride in a wax matrix
[76]. Triamterene appears to be somewhat less effec-
tive in restoring normal plasma composition in such
patients [76]. Attempts to raise total body potassium
with potassium supplements in edematous potassium
deficient patients have generally failed [26, 58, 60],
presumably because the deficit is in part a reflection
of a reduction in tissue mass. However, in many
edematous patients, particularly those with liver and
heart disease, potassium-sparing diuretics restore
plasma potassium concentration to normal levels and
maintain normal levels during therapy with thiazide
or loop diuretics. Clinical experience shows that
potassium chloride administration has the same ef-
fect if sufficient amounts are given.
The effectiveness of the various salts of potassium
in the potassium-deficient patient with metabolic al-
kalosis has been alluded to earlier. In such patients,
metabolic alkalosis and potassium deficiency persist
as long as the intake of chloride remains restricted
despite the availability of large amounts of potassium
in the diet. Administration of supplemental potas-
sium as the citrate, gluconate, or acetate salt,
even in large doses, fails to correct totally the potas-
sium deficit. Full correction is readily achieved, how-
ever, with potassium chloride or with any other po-
tassium preparation as long as some source of
chloride is available to correct the chloride depletion
[II].
Risks of treatment
Oral potassium supplements. The major risks of
therapy with potassium supplements are hyperka-
lemic cardiac arrest and small bowel ulceration. Car-
diac arrest is obviously the most serious risk. Severe
hyperkalemia is more likely to occur when potassium
is being administered iv. either to patients with renal
insufficiency or to those with rapidly changing acid-
base status.,for example, as seen occasionally follow-
ing cardiac surgery [77]. Cardiac arrest, however, has
been reported in patients with heart disease following
oral potassium ingestion with single doses as low as
40 mEq and daily doses as small as 180 mEq [78], and
it may occur even in normal individuals if the dose is
sufficiently great (for example, a single dose of 500
mEq) [79].
A quantitative estimate of the risk of potassium
therapy has been provided from data collected in a
hospital-based drug surveillance program in which
the records from 16,000 consecutive patients were
studied [63]. Of this group, approximately 4,900 pa-
tients had received potassium chloride (86% of the
patients had been given the supplement to prevent,
rather than to treat, hypokalemia). Hyperkalemia
occurred in 176 treated patients. Seven of these pa-
tients died from hyperkalemia, and it was estimated
that the lives of an additional 21 patients were
"threatened" by hyperkalemia, giving an all-over fre-
quency of fatal or life-threatening hyperkalemia in
hospitalized patients receiving potassium of approxi-
in ately I in 200! The frequency of hyperkalemia was
highest in the elderly, in patients with impaired renal
function, in those receiving simultaneous oral and i.v.
supplements, and in those receiving potassium chlo-
ride along with diuretics. Surprisingly, no difference
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was detected in the frequency of hyperkalemia in
those treated with potassium-sparing or potassium-
depleting diuretics.
Small bowel ulceration is another serious compli-
cation of potassium replacement therapy. The evi-
dence is quite clear that the risk of this complication
is related to the preparation of potassium chloride
employed. Although many liquid potassium prepara-
tions are unpalatable, instances of gastrointestinal
ulceration attributed to their use are rare. Many cases
of small bowel ulceration, however, have been re-
ported from the ingestion of enteric-coated potas-
sium chloride tablets and enteric-coated combina-
tions of thiazide diuretics and potassium chloride
[80—83]. The risk of ulceration from these prepara-
tions has been estimated to be 40 to 50 per 100,000
patient-years, and, for this reason, the Food and
Drug Administration has recently recommended
withdrawing all such formulations from the market
in the United States [84]. The risk of intestinal ulcers,
coupled with the problem of acceptability and com-
pliance in patients given oral preparations of potas-
sium chloride [85], led to the search for a safe tablet
form of potassium chloride. The newest preparation
is sugar-coated, contains 8 mEq of potassium chlo-
ride in a wax matrix, and is fully absorbed [86, 87].
The most popular of these wax-i mbedded potassium
chloride preparations has achieved widespread use
over the past eleven years, yet until early 1976 only a
dozen or so cases of small bowel lesions and/or
gastrointestinal bleeding have been thought to be
caused by this preparation (WETTER MS, personal
communication). Assuming a daily dose of 20 mEq/
day, the incidence of small bowel lesions from wax
matrix-imbedded potassium chloride appears to be in
the range of 0.2 per 100,000 patient-years, a rate con-
siderably lower than that for "enteric-coated" potas-
sium chloride preparations. Because of two recent
reports of esophageal ulceration in patients with par-
tial esophageal obstruction, the wax matrix prepara-
tion should be avoided in patients with impaired
esophageal emptying [88, 89].
Potassium-sparing diuretics. As part of the same
drug surveillance program described previously, it
was found that 9% of almost 800 hospitalized medi-
cal patients receiving spironolactone developed clini-
cally important hyperkalemia [90]. In virtually every
instance, spironolactone had been administered in
conjunction with other diuretics. Hyperkalemia oc-
curred in 16% of those who received potassium chlo-
ride concurrently, compared to 6% of those not re-
ceiving potassium supplements, It is notable that 42%
of spironolactone- and potassium-treated patients
whose blood urea nitrogen was greater than 50
nig/100 ml became hyperkalemic. In one-third of the
hyperkalemic patients, treatment with exchange res-
ins was required, and in two patients drug-induced
hyperkalemia appeared to play a role in the patients'
deaths. Hyperkalemia is much less frequent in pa-
tients with cirrhosis who are given potassium-sparing
diuretics, in part because of the very high circulating
levels of aldosterone in such patients [91]. Hyper-
kalemia has also been noted in patients treated either
with amiloride or triamterene.
Patients with diabetes mellitus who for any reason
have a concomitant defect in distal potassium secre-
tion have a special propensity to develop hyperka-
lemia when given glucose [92-95]. In two recently
reported patients with diabetes complicated by
hypoaldosteronism, severe hyperkalemia developed
when blood glucose was elevated [92]. Similarly, it
has been shown that the routine administration of i.v.
glucose to comatose diabetic patients previously
treated with triamterene can also result in life-threat-
ening hyperkalemia [93]. Two instances of severe
hyperkalemia (one of which was fatal) were also noted
in four diabetic patients receiving amiloride in a
daily dose of 20 mg [94]. Neither patient with hyper-
kalemia had renal insufficiency, and neither had re-
ceived large doses of potassium. The mechanism of
this disturbance has not yet been elucidated, but care-
ful monitoring of blood glucose and serum potassium
concentration is essential in any diabetic patient with
a defective distal exchange mechanism resulting ei-
ther from disordered adrenal steroid metabolism or
blockade by aldosterone antagonists or other agents.
Data on the risks of hyperkalemia in patients re-
ceiving potassium supplements or potassium-sparing
diuretics have been derived from a population of
hospitalized patients who are probably more suscep-
tible to the development of hyperkalemia because of
factors such as advanced age, impaired renal func-
tion, and exposure to i.v. potassium therapy. Al-
though comparable data are unavailable, it seems
likely that even in the ambulatory patient receiving
these agents, there is a small but important risk of
serious hyperkalemia.
Dollar cost. The expense of potassium supplemen-
tation (assuming a dose of 50 mEq/day) in Boston is
shown for several such formulations in Table 2. The
expense of potassium-sparing diuretics in doses usu-
ally recommended to prevent hypokalemia is also
shown. To supply an additional intake of 50
mEq/day, it is estimated that one liter of freshly
squeezed orange juice or four to six bananas must be
ingested. It should be pointed out that the efficacy of
increasing fruit or fruit juice intake in the repair of
potassium deficiency has not been demonstrated.
512 Kassirer and Harrington
Table 2. Dollar cost ol' potassium therapy (50 mEq/day)
Preparation Manufacturer Contents
Approx. retail cost per month,
dollars
10% potassium chloride
Kaochlor
K-Lor
Kay Ciel
Slow K
Several manufacturers
Warren-Teed
Abbott
Cooper
Ciba
potassium chloride
potassium chloride
potassium chloride
potassium chloride
potassium chloride
9 to 13
13 to 16
II to 16
II to IS
S to 12
Kaon
Potassium triplex
K-Lyte
Warren-Teed
Lilly
Mead Johnson
potassium gluconatc
potassium acetate
potassium bicarbonate
potassium Citrate
potassium citrate
15 to 18
5 to 7
12 to 16
Orange juice, I liter/day
Bananas, 4 to 6/day
— — 15 to 25
15 to 20
Aldactone. 100 mg/day
Dyrenium, 300 mg/day
Searle
Smith, Klein & French
Spironolactone
Triamterene
13 to 16
10 to 14
Summary and recommendations
The lack of clear evidence of clinically important
potassium depletion in the nonedematous patient
treated with diuretics, coupled with a small risk of life-
threatening hyperkalemia, leads us to conclude that
neither potassium-sparing diuretics nor potassium
supplementation should be given routinely to such
patients. it seems rational to recommend instead that
serum potassium concentration should be monitored
prior to therapy and at one to two-month intervals
thereafter until a pattern emerges.a If the serum po-
tassium concentration remains above 3.0 mEq/liter,
there is little justification to attempt to change the
potassium concentration, unless symptoms clearly at-
tributable to potassium deficiency develop. In the
rare instance in which serum potassium concentra-
tion falls below 3.0 mEq/liter, administration of 10%
potassium chloride solution, 50 to 60 mEq/day by
mouth, is an inexpensive and effective means of re-
storing normal potassium balance in most patients.
Wax-matrix formulations of potassium chloride ap-
pear to be safe, well-tolerated, and can be given to
patients who are intolerant of oral potassium chlo-
ride solutions. If distal-blocking agents are used,
careful monitoring of serum potassium concentration
is certainly in order. Distal-blocking agents should be
given to patients with renal functional impairment
only with great caution because of the substantial risk
of hyperkalemia.
The data arc conflicting in edematous patients.
Nevertheless, the value of restoring potassium bal-
ance appears to outweigh the risk of treatment with
We have assumed that the diagnosis of primary aldosteronism
has been considered and for practical purposes excluded prior to
institution of diuretic therapy.
potassium salts or potassium-sparing diuretics. Ther-
apy is probably warranted in patients receiving digi-
tails and in those susceptible to developing hepatic
coma. In such patients, an oral potassium chloride
supplement usually suffices to correct the deficit.
Mild deficits are usually corrected by giving 40 to 80
mEq/day, and more severe deficits may require as
mitch as 100 to 120 mEq/day with careful monitoring
of the serum concentration. If serum potassium con-
centration does not increase with an oral potassium
supplement, a distal-blocking agent can be used in-
stead of the supplement. Spironolactone is quite ef-
fective hut it is fairly expensive, and if prolonged
therapy is required it may cause gynecomastia.
Triamterene is less expensive but it also may be less
effective, and its use may be complicated by intoler-
able gastrointestinal side effects or a rash. Amiloride
has some possible value, but it is not yet available in
some countries.
As noted before, potassium chloride administra-
tion is more dangerous in the elderly, in patients with
impaired renal function, and in those receiving distal-
blocking agents. Potassium chloride and distal-block-
ing agents should be used together only in patients
with severe refractory potassium deficiency, and
when this combination is utilized, frequent mon-
itoring of the serum potassium concentration is man-
datory.
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